Ensuring Patient Access and Effective Drug Enforcement Act

Last updated

Ensuring Patient Access and Effective Drug Enforcement Act
Great Seal of the United States (obverse).svg
Enacted bythe 114th United States Congress
Citations
Public law Pub.L.   114–145 (text) (PDF)
Legislative history
  • Introduced in the Senate as the "Enduring Patient Access and Effective Drug Enforcement Act of 2015" (S. 483) by Orrin Hatch (RUT) on February 12, 2015
  • Committee consideration by Senate Judiciary Committee
  • Passed the Senate on March 17, 2016 
  • Passed the House on April 12, 2016 
  • Signed into law by President Barack Obama on April 19, 2016

The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 is a United States federal statute enacted by the 114th United States Congress and signed into law by President Barack Obama on April 19, 2016. It modified the Controlled Substances Act, which requires the Drug Enforcement Administration (DEA) to identify "imminent danger to the public health and safety" before suspending the registration of a manufacturer, distributor, or dispenser for controlled substances privileges. [1]

It "hampered the DEA's ability to seize suspicious shipments [of opioids]" within the context of the opioid epidemic. [2]

It was cosponsored by Sen. Sheldon Whitehouse [D-RI], Sen. Marco Rubio [R-FL], Sen. David Vitter [R-LA], Rep. Marsha Blackburn and Sen. Bill Cassidy [R-LA].

An earlier iteration of the bill was introduced by Rep. Tom Marino [R-PA] and passed the House of Representatives in 2015. [3] This was purportedly the reason behind Marino's withdrawal of his candidacy for Director of the Office of National Drug Control Policy (aka drug czar). [4]

It has been reported on by various news agencies including the Washington Post, [5] Fox News, [6] USA Today, [7] and the story was originally broken by CBS/60 Minutes. [8]

Related Research Articles

Controlled Substances Act United States drug-regulating law

The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs.

Drug Enforcement Administration United States federal law enforcement agency

The Drug Enforcement Administration is a United States federal law enforcement agency under the U.S. Department of Justice tasked with combating drug trafficking and distribution within the U.S. It is the lead agency for domestic enforcement of the Controlled Substances Act, sharing concurrent jurisdiction with the Federal Bureau of Investigation, the U.S. Immigration and Customs Enforcement, and U.S. Customs and Border Protection. The DEA has sole responsibility for coordinating and pursuing U.S. drug investigations both domestically and abroad.

Orrin Hatch American politician (1934–2022)

Orrin Grant Hatch was an American attorney and politician who served as a United States senator from Utah from 1977 to 2019. Hatch's 42-year Senate tenure made him the longest-serving Republican U.S. senator in history. Hatch was also a lifelong member of The Church of Jesus Christ of Latter-day Saints.

Pentazocine Opioid medication

Pentazocine, sold under the brand name Talwin among others, is a painkiller used to treat moderate to severe pain. It is believed to work by activating (agonizing) κ-opioid receptors (KOR) and μ-opioid receptors (MOR). As such it is called an opioid as it delivers its effects on pain by interacting with the opioid receptors. It shares many of the side effects of other opioids like constipation, nausea, itching, drowsiness and respiratory depression, but unlike most other opioids it fairly frequently causes hallucinations, nightmares and delusions. It is also, unlike most other opioids, subject to a ceiling effect, which is when at a certain dose no more pain relief, or side effects, is obtained by increasing the dose any further.

Office of National Drug Control Policy United States government agency

The Office of National Drug Control Policy (ONDCP) is a component of the Executive Office of the President of the United States.

Carfentanil Chemical compound

Carfentanil or carfentanyl, sold under the brand name Wildnil, is an opioid analgesic which is used in veterinary medicine to anesthetize large animals such as elephants and bears. It is typically administered in this context by tranquilizer dart. Carfentanil has also been used in humans for imaging of opioid receptors. It has additionally been encountered as an illicit drug, typically used by injection, insufflation, or inhalation. Deaths have been reported in association with carfentanil.

Cardinal Health American multinational health care services company

Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States. Its headquarters are in Dublin, Ohio and Dublin, Ireland (EMEA). The company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical products, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest network of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.

Drug diversion is a medical and legal concept involving the transfer of any legally prescribed controlled substance from the individual for whom it was prescribed to another person for any illicit use. The definition varies slightly among different jurisdictions, but the transfer of a controlled substance alone usually does not constitute a diversion, since certain controlled substances that are prescribed to a child are intended to be administered by an adult, as directed by a medical professional. The term comes from the "diverting" of the drugs from their original licit medical purpose. In some jurisdictions, drug diversion programs are available to first time offenders of diversion drug laws, which "divert" offenders from the criminal justice system to a program of education and rehabilitation.

Removal of cannabis from Schedule I of the Controlled Substances Act Proposed change to the Controlled Substances Act in the United States

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act, the most tightly restricted category reserved for drugs that have "no currently accepted medical use,” has been proposed repeatedly since 1972.

Dihydromorphine Chemical compound (semi-synthetic opioid)

Dihydromorphine is a semi-synthetic opioid structurally related to and derived from morphine. The 7,8-double bond in morphine is reduced to a single bond to get dihydromorphine. Dihydromorphine is a moderately strong analgesic and is used clinically in the treatment of pain and also is an active metabolite of the analgesic opioid drug dihydrocodeine. Dihydromorphine occurs in trace quantities in assays of opium on occasion, as does dihydrocodeine, dihydrothebaine, tetrahydrothebaine, etc. The process for manufacturing dihydromorphine from morphine for pharmaceutical use was developed in Germany in the late 19th century, with the synthesis being published in 1900 and the drug introduced clinically as Paramorfan shortly thereafter. A high-yield synthesis from tetrahydrothebaine was later developed.

Salvia divinorum, a psychoactive plant, is legal in most countries. Exceptions, countries where there is some form of control, include Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Italy, Japan, South Korea, Norway, Poland, United Kingdom, Ukraine, Spain, Sweden, Armenia and 33 states and territories of the United States.

Legal history of cannabis in the United States Aspect of history

The legal history of cannabis in the United States pertains to the regulation of cannabis for medical, recreational, and industrial purposes in the United States. Increased restrictions and labeling of cannabis as a poison began in many states from 1906 onward, and outright prohibitions began in the 1920s. By the mid-1930s cannabis was regulated as a drug in every state, including 35 states that adopted the Uniform State Narcotic Drug Act. The first national regulation was the Marihuana Tax Act of 1937.

Medical cannabis in the United States Use of cannabis for medical purposes in the United States

In the United States, the use of cannabis for medical purposes is legal in 37 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of February 2022. Eleven other states have more restrictive laws limiting THC content, for the purpose of allowing access to products that are rich in cannabidiol (CBD), a non-psychoactive component of cannabis. There is significant variation in medical cannabis laws from state to state, including how it is produced and distributed, how it can be consumed, and what medical conditions it can be used for.

Tom Marino Representative for Pennsylvanias 10th congressional district

Thomas Anthony Marino is an American politician and attorney. He served four terms and a minor part of his fifth term as a United States Representative from Pennsylvania, for Pennsylvania's 10th congressional district from January 3, 2011, to January 3, 2019, and for Pennsylvania's 12th congressional district from January 3 to January 23, 2019. A member of the Republican Party, Marino was the United States Attorney for the United States District Court for the Middle District of Pennsylvania in his early career.

21st Century Cures Act

The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations.

Opioid epidemic in the United States Ongoing overuse of opioid medication in the US

The opioid epidemic is the extensive ongoing overuse of opioid medications, both from medical prescriptions and from illegal sources. The epidemic began in the United States in the late 1990s, according to the Centers for Disease Control and Prevention (CDC), when opioids were increasingly prescribed for pain management and resulted in a rise in overall opioid use throughout subsequent years. The great majority of Americans who use prescription opioids do not believe that they are misusing them.

Drug disposal Safe disposal of unused drugs

Drug disposal is the discarding of drugs. Individuals commonly dispose of unused drugs that remain after the end of medical treatment. Health care organizations dispose of drugs on a larger scale for a range of reasons, including having leftover drugs after treating patients and discarding of expired drugs. Failure to properly dispose of drugs creates opportunities for others to take them inappropriately. Inappropriate disposal of drugs can also cause drug pollution.

SUPPORT for Patients and Communities Act, also known as Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act, is a United States federal law, enacted during the 115th United States Congress, to make medical treatment for opioid addiction more widely available while also cracking down on illicit drugs. This piece of legislation is part of the ongoing conflict to stop and prevent the opioid epidemic in the United States. President Trump signed the bill on October 24, 2018.

Opioid epidemic Type of drug epidemic

The opioid epidemic, also referred to as the opioid crisis, is the phrase used to describe the overuse, misuse/abuse, and overdose deaths attributed either in part or in whole to the class of drugs opiates/opioids, and the significant medical, social, psychological, and economic consequences of the medical, non-medical, and recreational use of these medications.

<i>The Crime of the Century</i> (2021 film) American documentary film

The Crime of the Century is an American two-part documentary film, directed, produced, and written by Alex Gibney. The film follows the opioid epidemic in the United States, and the political operatives, government regulations and corporations that enable the abuse of opioids, particularly the Sackler family and Purdue Pharma.

References

  1. "S.483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2016". April 19, 2016. Retrieved October 22, 2017.
  2. "Who Profits from the Opioid Crisis? Meet the Secretive Sackler Family Making Billions from OxyContin" (Streamable Video). Democracy Now!. October 19, 2017. Retrieved October 22, 2017.
  3. "H.R.471 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015". April 22, 2015. Retrieved October 22, 2017.
  4. "Tom Marino, Trump's Pick As Drug Czar, Withdraws After Damaging Opioid Report". The Two Way. NPR. October 17, 2017. Retrieved October 22, 2017.
  5. Higham, Scott; Bernstein, Lenny (October 16, 2017). "Did President Obama know bill would strip DEA of power?". The Washington Post. Retrieved November 12, 2017.
  6. Llorente, Elizabeth (October 17, 2017). "Little-noticed law drug companies fought for: How it passed amid opioid crisis, what it does". Fox News. Retrieved November 12, 2017.
  7. Gray, John (October 17, 2017). "Drug law hasn't hurt enforcement". USA Today. Retrieved November 12, 2017.
  8. Whitaker, Bill (October 15, 2017). "Ex-DEA agent: Opioid crisis fueled by drug industry and Congress". CBS News. Retrieved November 12, 2017.